Evaluation of the stability of morphine sulphate in combination with Instillagel

N.S. Labyad, D.G. Watson, M. Pournamdari, C.G. Cable, E. Stanley

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background and objective: The Pharmacy Department at the Western General Hospital in Edinburgh prepares a topically applied product in which morphine sulphate is incorporated into Instillagel® for use in reducing pain associated with rectal and other cancers. A stability indicating method was required for assessment of the stability of this combination. Methods: A gradient high performance liquid chromatography method was developed to assess stability and an LC-MS method was used to characterize the degradants from forced degradation of the components in the formulation. Results and discussion: The method was found to have acceptable inter- and intra-day precisions. Under all storage conditions investigated morphine sulphate remained within 98·1% and 103·2% of the initial concentration, lidocaine hydrochloride within 96·07% and 104·9% and chlorhexidine gluconate within 97·3% and 105·5%, except for samples stored at 37 °C beyond 240 h. A sample of the admixture was stored up to 7 months at 37 °C and was found to be reasonably stable with only the chlorhexidine concentration declining appreciably to 92% of the initial concentration. Some of the degradants of chlorhexidine and morphine were characterized by liquid chromatography mass spectrometry. It could be concluded that the admixture was stable for over 22 days at 4 °C protected from light, over 22 days at 25 °C exposed to normal light, and for 7 months at 37 °C protected from light.
LanguageEnglish
Pages263-271
Number of pages8
JournalJournal of Clinical Pharmacy and Therapeutics
Volume33
Issue number3
DOIs
Publication statusPublished - 4 Jan 2008

Fingerprint

Morphine
Chlorhexidine
Light
Rectal Neoplasms
Lidocaine
Liquid Chromatography
General Hospitals
Mass Spectrometry
High Pressure Liquid Chromatography
lidocaine drug combination chlorhexidine gluconate
Pain

Keywords

  • chlorhexidine
  • gel
  • lidocaine
  • stability
  • morphine
  • chromatography

Cite this

Labyad, N.S. ; Watson, D.G. ; Pournamdari, M. ; Cable, C.G. ; Stanley, E. / Evaluation of the stability of morphine sulphate in combination with Instillagel. In: Journal of Clinical Pharmacy and Therapeutics. 2008 ; Vol. 33, No. 3. pp. 263-271.
@article{cf8046867df44656b93017aa4f0b92b7,
title = "Evaluation of the stability of morphine sulphate in combination with Instillagel",
abstract = "Background and objective: The Pharmacy Department at the Western General Hospital in Edinburgh prepares a topically applied product in which morphine sulphate is incorporated into Instillagel{\circledR} for use in reducing pain associated with rectal and other cancers. A stability indicating method was required for assessment of the stability of this combination. Methods: A gradient high performance liquid chromatography method was developed to assess stability and an LC-MS method was used to characterize the degradants from forced degradation of the components in the formulation. Results and discussion: The method was found to have acceptable inter- and intra-day precisions. Under all storage conditions investigated morphine sulphate remained within 98·1{\%} and 103·2{\%} of the initial concentration, lidocaine hydrochloride within 96·07{\%} and 104·9{\%} and chlorhexidine gluconate within 97·3{\%} and 105·5{\%}, except for samples stored at 37 °C beyond 240 h. A sample of the admixture was stored up to 7 months at 37 °C and was found to be reasonably stable with only the chlorhexidine concentration declining appreciably to 92{\%} of the initial concentration. Some of the degradants of chlorhexidine and morphine were characterized by liquid chromatography mass spectrometry. It could be concluded that the admixture was stable for over 22 days at 4 °C protected from light, over 22 days at 25 °C exposed to normal light, and for 7 months at 37 °C protected from light.",
keywords = "chlorhexidine, gel, lidocaine, stability, morphine, chromatography",
author = "N.S. Labyad and D.G. Watson and M. Pournamdari and C.G. Cable and E. Stanley",
year = "2008",
month = "1",
day = "4",
doi = "10.1111/j.1365-2710.2008.00914.x",
language = "English",
volume = "33",
pages = "263--271",
journal = "Journal of Clinical Pharmacy and Therapeutics",
issn = "0269-4727",
number = "3",

}

Evaluation of the stability of morphine sulphate in combination with Instillagel. / Labyad, N.S.; Watson, D.G.; Pournamdari, M.; Cable, C.G.; Stanley, E.

In: Journal of Clinical Pharmacy and Therapeutics, Vol. 33, No. 3, 04.01.2008, p. 263-271.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Evaluation of the stability of morphine sulphate in combination with Instillagel

AU - Labyad, N.S.

AU - Watson, D.G.

AU - Pournamdari, M.

AU - Cable, C.G.

AU - Stanley, E.

PY - 2008/1/4

Y1 - 2008/1/4

N2 - Background and objective: The Pharmacy Department at the Western General Hospital in Edinburgh prepares a topically applied product in which morphine sulphate is incorporated into Instillagel® for use in reducing pain associated with rectal and other cancers. A stability indicating method was required for assessment of the stability of this combination. Methods: A gradient high performance liquid chromatography method was developed to assess stability and an LC-MS method was used to characterize the degradants from forced degradation of the components in the formulation. Results and discussion: The method was found to have acceptable inter- and intra-day precisions. Under all storage conditions investigated morphine sulphate remained within 98·1% and 103·2% of the initial concentration, lidocaine hydrochloride within 96·07% and 104·9% and chlorhexidine gluconate within 97·3% and 105·5%, except for samples stored at 37 °C beyond 240 h. A sample of the admixture was stored up to 7 months at 37 °C and was found to be reasonably stable with only the chlorhexidine concentration declining appreciably to 92% of the initial concentration. Some of the degradants of chlorhexidine and morphine were characterized by liquid chromatography mass spectrometry. It could be concluded that the admixture was stable for over 22 days at 4 °C protected from light, over 22 days at 25 °C exposed to normal light, and for 7 months at 37 °C protected from light.

AB - Background and objective: The Pharmacy Department at the Western General Hospital in Edinburgh prepares a topically applied product in which morphine sulphate is incorporated into Instillagel® for use in reducing pain associated with rectal and other cancers. A stability indicating method was required for assessment of the stability of this combination. Methods: A gradient high performance liquid chromatography method was developed to assess stability and an LC-MS method was used to characterize the degradants from forced degradation of the components in the formulation. Results and discussion: The method was found to have acceptable inter- and intra-day precisions. Under all storage conditions investigated morphine sulphate remained within 98·1% and 103·2% of the initial concentration, lidocaine hydrochloride within 96·07% and 104·9% and chlorhexidine gluconate within 97·3% and 105·5%, except for samples stored at 37 °C beyond 240 h. A sample of the admixture was stored up to 7 months at 37 °C and was found to be reasonably stable with only the chlorhexidine concentration declining appreciably to 92% of the initial concentration. Some of the degradants of chlorhexidine and morphine were characterized by liquid chromatography mass spectrometry. It could be concluded that the admixture was stable for over 22 days at 4 °C protected from light, over 22 days at 25 °C exposed to normal light, and for 7 months at 37 °C protected from light.

KW - chlorhexidine

KW - gel

KW - lidocaine

KW - stability

KW - morphine

KW - chromatography

UR - http://dx.doi.org/10.1111/j.1365-2710.2008.00914.x

U2 - 10.1111/j.1365-2710.2008.00914.x

DO - 10.1111/j.1365-2710.2008.00914.x

M3 - Article

VL - 33

SP - 263

EP - 271

JO - Journal of Clinical Pharmacy and Therapeutics

T2 - Journal of Clinical Pharmacy and Therapeutics

JF - Journal of Clinical Pharmacy and Therapeutics

SN - 0269-4727

IS - 3

ER -